← SynDRA
APAFANT
SynDRA canonical compound SYN0001184 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | PTAFR |
|---|
| Mechanism of action | Platelet activating factor receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- Platelet activating factor receptor antagonist
- PTAFR ANTAGONIST
- PTAFR MODULATOR
Drug classes
- Fibrinolytic Agents
- Platelet Aggregation Inhibitors
Cross-references
Synonyms
- DE-081
- WEB-2086
- WEB-2086-BS
- WEB2086
- Web 2086
- Apafant [USAN:INN]
- Apafantum [INN-Latin]
- Apafanto [INN-Spanish]
- WEB 2086BS
- UNII-J613NI05SV
- WEB 2086 BS
- BRN 4302553
- C22H22ClN5O2S
- J613NI05SV
- CHEMBL280164
- NCGC00092377-03
- NCGC00092377-02
- Apafantum
- Apafanto
- DSSTox_CID_28900
- DSSTox_RID_83168
- DSSTox_GSID_48974
- 4-(3-(4-(o-Chlorophenyl)-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepin-2-yl)propionyl)morpholine
- [3H]apafant
- Morpholine
- Apafant (ophthalmic formulation), Santen
- triazolodiazepine
- Apafant [INN]
- APAFANT [JAN]
- APAFANT [USAN]
- APAFANT [MI]
- APAFANT [MART.]
- DTXCID5028900
- Apafantum (INN-Latin)
- Apafanto (INN-Spanish)
- APAFANT (MART.)
- RefChem:558390
- CAS-105219-56-5
Look up APAFANT in the interactive SynDRA portal →